Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.

Archives of pharmacal research - 1 Nov 2020

Bae Jung-Woo, Oh Kyung-Yul, Yoon So-Jung, Shin Hyo-Bin, Jung Eui Hyun, Cho Chang-Keun, Lim Chang Woo, Kang Pureum, Choi Chang-Ik, Jang Choon-Gon, Lee Seok-Yong, Lee Yun Jeong

Abstract excerpt

Metoclopramide inhibits the central and peripheral D2 receptors and is frequently prescribed in adults and children as an antiemetic or a prokinetic drug to control symptoms of upper gastrointestinal motor disorders. Metoclopramide is predominantly metabolized via N-dealkylation and it is primarily mediated by CYP2D6 which is highly polymorphic. Thus, the effects of CYP2D6 genetic polymorphism on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Cytochrome P-450 CYP2D6

Share to Models, Biological

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Spectrophotometry, Ultraviolet

Source

Identifiers

PMID: 33247397
DOI: 10.1007/s12272-020-01293-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.PMID 33247397Read ↗

CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.Semantic proximity Read ↗

Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.Semantic proximity Read ↗

Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.Semantic proximity Read ↗

Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.Semantic proximity Read ↗

The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Semantic proximity Read ↗

Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.